. home.aspx

NEWS

home.aspx
   


FDA recommends LC-HRMS to test for NDMA in ranitidine products

October 03, 2019 / Victoria Rees
SHARESHARESHARE

The US Food and Drug Administration (FDA) has announced an update on its method recommendation of testing for NDMA in ranitidine medication products. The ingredient is a probable human carcinogen. A previous method published by the FDA for testing angiotensin II receptor blockers (ARBs) for nitrosamine impurities has been utilised by a third-party laboratory to test ranitidine products. However, this uses high temperatures which results in ranitidine generating NDMA. Therefore, the FDA has recommended using a Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) technique to test samples as this does not use high temperatures. These tests have shown the presence of much lower levels of NDMA in ranitidine products than the third-party laboratory. Other international regulators using a similar LC-MS method have also demonstrated low levels of NDMA in ranitidine samples.